Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets

References

• Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004; 20: 33–43
   PubMed Web of Science ®Google Scholar
• Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol. 2005; 53: 430–42
   PubMed Web of Science ®Google Scholar
• Veit G, Kobbe B, Keene DR, Paulsson M, Koch M, Wagener R. Collagen XXVIII, a novel von Willebrand factor A domain-containing protein with many imperfections in the collagenous domain. J Biol Chem. 2006; 281: 3494–504
   PubMed Web of Science ®Google Scholar
• Söderhäll C, Marenholz I, Kerscher T, Rüschendorf S, Esparza-Gordillo J, Worm M, et al. Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. PLoS Biol. 2007; 5: e242
   PubMed Web of Science ®Google Scholar
• Kivirikko KI, Myllyharju J. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biol. 1998; 16: 357–68
   PubMed Web of Science ®Google Scholar
• Kivirikko KI, Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol. 1998; 72: 325–98
   PubMedGoogle Scholar
• Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003; 22: 15–24
   PubMed Web of Science ®Google Scholar
• Myllyharju J. Intracellular post-translational modifications of collagens. Top Curr Chem. 2005; 247: 115–47
   Google Scholar
• Kukkola L, Hieta R, Kivirikko KI, Myllyharju J. Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003; 278: 47685–93
   PubMed Web of Science ®Google Scholar
• Van Den Diepstraten C, Papay K, Bolender Z, Brown A, Pickering JG. Cloning of a novel prolyl 4-hydroxylase subunit expressed in the fibrous cap of human atherosclerotic plaque. Circulation. 2003; 108: 508–11
   PubMed Web of Science ®Google Scholar
• Annunen P, Koivunen P, Kivirikko KI. Cloning of the α subunit of prolyl 4-hydroxylase from Drosophila and expression and characterization of the corresponding enzyme tetramer with some unique properties. J Biol Chem. 1999; 274: 6790–6
   PubMedGoogle Scholar
• Keskiaho K, Kukkola L, Page AP, Winter AD, Vuoristo J, Sormunen R, , et al Characterization of a novel Caenorhabditis elegans prolyl 4-hydroxylase with a unique substrate specificity and restricted expression in the pharynx and excretory duct. J Biol Chem. 2008, in press.
   Google Scholar
• Myllyharju J, Kukkola L, Winter AD, Page AP. The exoskeleton collagens in Caenorhabditis elegans are modified by prolyl 4-hydroxylases with unique combinations of subunits. J Biol Chem. 2002; 277: 29187–96
   Google Scholar
• Riihimaa P, Nissi R, Page AP, Winter AD, Keskiaho K, Kivirikko KI, et al. Egg shell collagen formation in Caenorhabditis elegans involves a novel prolyl 4-hydroxylase expressed in spermatheca and embryos and possessing many unique properties. J Biol Chem. 2002; 277: 18238–43
   Google Scholar
• Abrams EW, Mihoulides WK, Andrew DJ. Fork head and Sage maintain a uniform and patent salivary gland lumen through regulation of two downstream target genes, PH4alphaSG1 and PH4alphaSG2. Development. 2006; 133: 3517–27
   Google Scholar
• Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292: 464–8
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468–72
   PubMed Web of Science ®Google Scholar
• Yu F, White SB, Zhao Q, Lee FS. HIF-1α is regulated by stimulus sensitive proline hydroxylation. Proc Natl Acad Sci USA. 2001; 98: 9630–5
   PubMed Web of Science ®Google Scholar
• Bruick RK, McKnight SL. A conserved family of prolyl 4-hydroxylases that modify HIF. Science. 2001; 294: 1337–40
   PubMed Web of Science ®Google Scholar
• Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107: 43–54
   PubMed Web of Science ®Google Scholar
• Ivan M, Haberberger T, Gervasi DC, Michelson KS, Günzler V, Kondo K, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA. 2002; 99: 13459–64
   PubMed Web of Science ®Google Scholar
• Centanin L, Ratcliffe PJ, Wappner P. Reversion of lethality and growth defects in Fatiga oxygen-sensor mutant flies by loss of hypoxia-inducible factor-α/Sima. EMBO Rep. 2005; 6: 1070–5
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5: 343–54
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 2005; 338: 617–26
   PubMed Web of Science ®Google Scholar
• Kaelin WG, Jr. Proline hydroxylation and gene expression. Annu Rev Biochem. 2005; 74: 115–28
   PubMed Web of Science ®Google Scholar
• Ozer A, Bruick RK. Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?. Nat Chem Biol. 2007; 3: 144–53
   PubMed Web of Science ®Google Scholar
• Siddiq A, Aminova LR, Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res. 2007; 32: 931–46
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001; 107: 1–3
   PubMed Web of Science ®Google Scholar
• Hofbauer K-H, Gess B, Lohaus C, Meyer HE, Katschinski D, Kurtz A. Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur J Biochem. 2003; 270: 4515–22
   PubMedGoogle Scholar
• Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res. 2005; 65: 3299–306
   PubMed Web of Science ®Google Scholar
• Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition. The role of HIF-1α, HIF-2α, and other pathways. J Biol Chem. 2006; 281: 15215–26
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le Q-T, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440: 1222–6
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. Understanding hypoxia signalling in cells—a new therapeutic opportunity?. Clin Med. 2006; 6: 573–8
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia?. J Clin Invest. 2007; 117: 862–5
   PubMed Web of Science ®Google Scholar
• Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol. 2003; 23: 9361–74
   PubMed Web of Science ®Google Scholar
• Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Wiesener M, Eckardt KU. Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J. 2004; 18: 1462–4
   PubMed Web of Science ®Google Scholar
• Gruber M, Hu C-J, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of HIF-2α results in anemia. Proc Natl Acad Sci U S A. 2007; 104: 2301–6
   PubMed Web of Science ®Google Scholar
• Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007; 117: 1068–77
   PubMed Web of Science ®Google Scholar
• Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hütter J, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun. 2002; 296: 343–9
   PubMed Web of Science ®Google Scholar
• Koivunen P, Tiainen P, Hyvärinen J, Williams KE, Sormunen R, Klaus SJ, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor α. J Biol Chem. 2007; 282: 30544–52
   PubMed Web of Science ®Google Scholar
• Vuorela A, Myllyharju J, Nissi R, Pihlajaniemi T, Kivirikko KI. Assembly of human prolyl 4-hydroxylase and type III collagen in the yeast Pichia pastoris: formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase. EMBO J. 1997; 16: 6702–12
   PubMed Web of Science ®Google Scholar
• Merle C, Perret S, Lacour T, Jonval V, Hudaverdian S, Garrone R, et al. Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant. FEBS Lett. 2002; 515: 114–8
   PubMed Web of Science ®Google Scholar
• Kersteen EA, Higgin JJ, Raines RT. Production of human prolyl 4-hydroxylase in Escherichia coli. Protein Expr Purif. 2004; 38: 279–91
   Google Scholar
• Neubauer A, Neubauer P, Myllyharju J. High-level production of human collagen prolyl 4-hydroxylase in Escherichia coli. Matrix Biol. 2005; 24: 59–68
   Google Scholar
• Lamberg A, Helaakoski T, Myllyharju J, Peltonen S, Notbohm H, Pihlajaniemi T, et al. Characterization of human type III collagen expressed in a baculovirus system. Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4-hydroxylase subunit. J Biol Chem. 1996; 271: 11988–95
   PubMed Web of Science ®Google Scholar
• Myllyharju J, Lamberg A, Notbohm H, Fietzek PP, Pihlajaniemi T, Kivirikko KI. Expression of wild-type and modified proα chains of human type I procollagen in insect cells leads to the formation of stable [α1(I)]2α2(I) collagen heterotrimers and [α1(I)]3 homotrimers but not [α2(I)]3 homotrimers. J Biol Chem. 1997; 272: 21824–30
   PubMed Web of Science ®Google Scholar
• Toman PD, Chisholm G, McMullin H, Giere LM, Olsen DR, Kovach RJ, et al. Production of recombinant human type I procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae. J Biol Chem. 2000; 275: 23303–9
   PubMed Web of Science ®Google Scholar
• Nokelainen M, Tu H, Vuorela A, Notbohm H, Kivirikko KI, Myllyharju J. High-level production of recombinant human type I collagen in the yeast Pichia pastoris. Yeast. 2001; 18: 797–806
   PubMed Web of Science ®Google Scholar
• Pakkanen O, Hämäläinen E-R, Kivirikko KI, Myllyharju J. Assembly of stable human type I and III collagen molecules from hydroxylated recombinant chains in the yeast Pichia pastoris. Effect of an engineered C-terminal oligomerization domain foldon. J Biol Chem. 2003; 278: 32478–83
   PubMedGoogle Scholar
• Myllyharju J, Kivirikko KI. Characterization of the iron- and 2-oxoglutarate-binding sites of human prolyl 4-hydroxylase. EMBO J. 1997; 16: 1173–80
   PubMed Web of Science ®Google Scholar
• Myllyharju J, Kivirikko KI. Identification of a novel proline-rich peptide-binding domain in prolyl 4-hydroxylase. EMBO J. 1999; 18: 306–12
   PubMed Web of Science ®Google Scholar
• Hieta R, Kukkola L, Permi P, Pirilä P, Kivirikko KI, Kilpeläinen I, et al. The peptide-substrate-binding domain of human collagen prolyl 4-hydroxylases. Backbone assignments, secondary structure, and binding of proline-rich peptides. J Biol Chem. 2003; 278: 34966–74
   PubMed Web of Science ®Google Scholar
• Pekkala M, Hieta R, Bergmann U, Kivirikko KI, Wierenga RK, Myllyharju J. The peptide-substrate-binding domain of collagen prolyl 4-hydroxylases is a tetratricopeptide repeat domain with functional aromatic residues. J Biol Chem. 2004; 279: 52255–61
   Google Scholar
• Nokelainen M, Nissi R, Kukkola L, Helaakoski T, Myllyharju J. Characterization of the human and mouse genes for the α subunit of type II prolyl 4-hydroxylase. Identification of a previously unknown alternative spliced exon and its expression in various tissues. Eur J Biochem. 2001; 268: 5300–9
   PubMedGoogle Scholar
• Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med. 2001; 33: 7–21
   PubMed Web of Science ®Google Scholar
• Grimmer C, Balbus N, Lang U, Aigner T, Cramer T, Müller L, et al. Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases. Possible influence of low oxygen levels. Am J Pathol. 2006; 169: 491–502
   PubMed Web of Science ®Google Scholar
• Holster T, Pakkanen O, Soininen R, Sormunen R, Nokelainen M, Kivirikko KI, et al. Loss of assembly of the main basement membrane collagen, type IV, but not fibril-forming collagens and embryonic death in collagen prolyl 4-hydroxylase I null mice. J Biol Chem. 2007; 282: 2512–9
   PubMed Web of Science ®Google Scholar
• Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen J, Stolze I, Klinger M, et al. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J Cell Sci. 2003; 116: 1319–26
   PubMed Web of Science ®Google Scholar
• McDonough MA, Li V, Flashman E, Chowdury R, Mohr C, Liénard BMR, et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA. 2006; 103: 9814–9
   PubMed Web of Science ®Google Scholar
• Choi K-O, Lee T, Lee N, Kim J-H, Yang EG, Yoon JM, et al. Inhibition of the catalytic activity of hypoxia-inducible factor-1α-prolyl-hydroxylase 2 by a MYND-type zinc finger. Mol Pharmacol. 2005; 68: 1803–9
   PubMedGoogle Scholar
• Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003; 278: 30772–80
   PubMed Web of Science ®Google Scholar
• Cervera AM, Apostolova N, Luna-Crespo F, Sanjuan-Pla A, Garcia-Pou R, McCreath KJ. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett. 2006; 233: 131–8
   Google Scholar
• Tian Y-M, Mole DR, Ratcliffe PJ, Gleadle JM. Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. Biochem J. 2006; 397: 179–86
   PubMed Web of Science ®Google Scholar
• Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol. 2002; 80: 421–6
   PubMed Web of Science ®Google Scholar
• Cioffi CL, Liu XQ, Kosinski PA, Garay M, Bowen BR. Differential regulation of HIF-1α prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun. 2003; 303: 947–53
   PubMed Web of Science ®Google Scholar
• Appelhoff RJ, Tian Y-M, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004; 279: 38458–65
   PubMed Web of Science ®Google Scholar
• Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006; 41: 68–77
   PubMed Web of Science ®Google Scholar
• Li N, Yi F, Sundy CM, Chen L, Hilliker ML, Donley DK, et al. Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol. 2007; 292: F207–16
   Google Scholar
• Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 2003; 22: 4082–90
   PubMed Web of Science ®Google Scholar
• D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C. Hypoxia up-regulates prolyl hydroxylase activity. A feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem. 2003; 278: 38183–7
   PubMed Web of Science ®Google Scholar
• del Peso L, Castellanos MC, Temes E, Martín-Puig S, Cuevas Y, Olmos G, et al. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem. 2003; 278: 48690–5
   PubMed Web of Science ®Google Scholar
• Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases. Biochem J. 2004; 381: 761–7
   PubMed Web of Science ®Google Scholar
• To KKW, Huang LE. Suppression of hypoxia-inducible factor 1α (HIF-1α) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem. 2005; 280: 38102–7
   PubMedGoogle Scholar
• Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem. 2006; 281: 23482–91
   PubMed Web of Science ®Google Scholar
• Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TRJ, Maxwell PH, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA. 2006; 103: 654–9
   PubMed Web of Science ®Google Scholar
• Percy MJ, Furlow PW, Beer PA, Lappin TR, McMullin MF, Lee FS. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood. 2007; 110: 2193–6
   PubMed Web of Science ®Google Scholar
• Takeda K, Ho VC, Takeda H, Duan L-J, Nagy A, Fong G-H. Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006; 26: 8336–46
   PubMed Web of Science ®Google Scholar
• Takeda K, Cowan A, Fong G-H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007; 116: 774–81
   PubMed Web of Science ®Google Scholar
• Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008; 111: 3229–35
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG, Jr. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008; 111: 3236–44
   PubMed Web of Science ®Google Scholar
• Aragonés J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008; 40: 170–80
   PubMed Web of Science ®Google Scholar
• Clifton IJ, McDonough MA, Ehrismann D, Kershaw DJ, Granatino N, Schofield CJ. Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix fold proteins. J Inorg Biochem. 2006; 100: 644–69
   PubMed Web of Science ®Google Scholar
• Keskiaho K, Hieta R, Sormunen R, Myllyharju J. Chlamydomonas reinhardtii has multiple prolyl 4-hydroxylases, one of which is essential for proper cell wall assembly. Plant Cell. 2007; 19: 256–69
   PubMed Web of Science ®Google Scholar
• Koski MK, Hieta R, Böllner C, Kivirikko KI, Myllyharju J, Wierenga RK. The active site of an algal prolyl 4-hydroxylase has a large structural plasticity. J Biol Chem. 2007; 282: 37112–23
   Google Scholar
• Hanauske-Abel HM, Popowicz AM. The HAG mechanism: a molecular rationale for the therapeutic application of iron chelators in human diseases involving the 2-oxoacid utilizing dioxygenases. Curr Med Chem. 2003; 10: 1005–19
   Google Scholar
• Tuckerman JR, Zhao Y, Hewitson KS, Tian Y-M, Pugh CW, Ratcliffe PJ, et al. Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS Lett. 2004; 576: 145–50
   Google Scholar
• Hirsilä M, Koivunen P, Xu L, Seeley T, Kivirikko KI, Myllyharju J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 2005; 19: 1308–10
   PubMed Web of Science ®Google Scholar
• Koivunen P, Hirsilä M, Kivirikko KI, Myllyharju J. The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J Biol Chem. 2006; 281: 28712–20
   PubMed Web of Science ®Google Scholar
• Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates. Possible links between cell metabolism and stabilization of HIF. J Biol Chem. 2007; 282: 4524–32
   PubMed Web of Science ®Google Scholar
• Ehrismann D, Flasman E, Genn DN, Mathioudakis N, Hewitson KS, Ratcliffe PJ, et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J. 2007; 401: 227–34
   PubMed Web of Science ®Google Scholar
• McNeill LA, Flashmann E, Buck MRG, Hewitson KS, Clifton IJ, Jeschke G, et al. Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol Biosyst. 2005; 1: 321–4
   PubMed Web of Science ®Google Scholar
• Acker H, Berchner-Pfannschmidt U, Wotzlaw C, Huckstorf C, Streller T. Optical analysis of the oxygen-sensing signal pathway. Oxygen Sensing, Responses and Adaptation to Hypoxia, S Lahiri, GL Semenza, NR Prabhakar. Marcel Dekker Inc, New York 2003; 507–21
   Google Scholar
• Kukkola L, Koivunen P, Pakkanen O, Page AP, Myllyharju J. Collagen prolyl 4-hydroxylase tetramers and dimers show identical decreases in Km values for peptide substrates with increasing chain length. Mutation of one of the two catalytic sites in the tetramer inactivates the enzyme by more than half. J Biol Chem. 2004; 279: 18656–61
   Google Scholar
• Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem. 2002; 277: 39792–800
   PubMed Web of Science ®Google Scholar
• Li D, Hirsilä M, Koivunen P, Brenner MC, Xu L, Yang C, et al. Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1α-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases. Substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation. J Biol Chem. 2004; 279: 55051–9
   PubMedGoogle Scholar
• Chan DA, Suthpin PD, Yen S-E, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible Factor 1α. Mol Cell Biol. 2005; 25: 6415–26
   PubMed Web of Science ®Google Scholar
• Flashman E, Bagg EA, Chowdhury R, Mecinovic J, Loenarz C, McDonough MA, et al. Kinetic rationale for selectivity toward N- and C-terminal oxygen-dependent degradation domain substrates mediated by a loop region of hypoxia-inducible factor prolyl hydroxylases. J Biol Chem. 2008; 283: 3808–15
   PubMed Web of Science ®Google Scholar
• Hon WC, Wilson MI, Harlos K, Claridge TDW, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature. 2002; 417: 975–8
   PubMed Web of Science ®Google Scholar
• Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, Sanchez Y, et al. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA. 2003; 100: 2706–11
   PubMed Web of Science ®Google Scholar
• Hanson ES, Rawlins ML, Leibold EA. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem. 2003; 278: 40337–42
   PubMed Web of Science ®Google Scholar
• Wang J, Chen G, Muckenthaler M, Galy B, Hentze MW, Pantopoulos K. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol. 2004; 24: 954–65
   PubMed Web of Science ®Google Scholar
• Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, et al. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFkB activity. Proc Natl Acad Sci U S A. 2006; 28: 18154–9
   Google Scholar
• Köditz J, Nesper J, Stiehl DP, Camenisch G, Franke C, Myllyharju J, et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood. 2007; 110: 3610–7
   PubMed Web of Science ®Google Scholar
• Masson N, Appelhoff RJ, Tuckerman JR, Tian YM, Demol H, Puype M, et al. The HIF prolyl hydroxylase PHD3 is a potential substrate of the TRiC chaperonin. FEBS Lett. 2004; 570: 166–70
   PubMedGoogle Scholar
• Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia. Cell. 2004; 117: 941–52
   PubMed Web of Science ®Google Scholar
• Nakayama K, Gazdoiu S, Abraham R, Pan ZQ, Ronai Z. Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem J. 2007; 401: 217–26
   PubMedGoogle Scholar
• Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, et al. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell. 2005; 17: 503–12
   PubMed Web of Science ®Google Scholar
• Ozer A, Wu LC, Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A. 2005; 102: 7481–6
   PubMed Web of Science ®Google Scholar
• Hopfer U, Hopfer H, Jablonski K, Stahl RA, Wolf G. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem. 2006; 281: 8645–55
   Google Scholar
• Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F, et al. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol. 2007; 27: 3758–68
   PubMed Web of Science ®Google Scholar
• Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today. 2004; 9: 704–11
   PubMed Web of Science ®Google Scholar
• Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-α hydroxylases. Curr Med Chem. 2007; 14: 1853–62
   PubMed Web of Science ®Google Scholar
• Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, Wenger RH. The antimycotic ciclopirox olamine induces HIF-1α stability, VEGF expression, and angiogenesis. FASEB J. 2003; 17: 761–3
   PubMed Web of Science ®Google Scholar
• Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia inducible factor-α. J Biol Chem. 2003; 278: 15911–6
   PubMed Web of Science ®Google Scholar
• Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem. 2004; 279: 40337–44
   PubMed Web of Science ®Google Scholar
• Cao M, Westerhausen-Larson A, Niyibizi C, Kavalkovich K, Georgescu HI, Rizzo CF, et al. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J. 1997; 324: 305–10
   PubMed Web of Science ®Google Scholar
• Metzen E, Zhou J, Jelkmann W, Fandrey J, Brüne B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl 4-hydroxylases. Mol Biol Cell. 2003; 14: 3470–81
   PubMed Web of Science ®Google Scholar
• Berchner-Pfannschmidt U, Yamac H, Trinidad B, Fandrey J. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem. 2007; 282: 1788–96
   Google Scholar
• Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004; 118: 781–94
   PubMed Web of Science ®Google Scholar
• Cash TP, Pan Y, Simon MC. Reactive oxygen species and cellular oxygen sensing. Free Radic Biol Med. 2007; 43: 1219–25
   PubMed Web of Science ®Google Scholar
• Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 2007; 27: 912–25
   PubMed Web of Science ®Google Scholar
• Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, Ratcliffe PJ, et al. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett. 2003; 13: 2677–80
   PubMed Web of Science ®Google Scholar
• Schlemminger I, Mole DR, McNeill LA, Dhanda A, Hewitson KS, Tian Y-M, et al. Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases. Bioorg Med Chem Lett. 2003; 13: 1451–4
   PubMed Web of Science ®Google Scholar
• Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Renock S, et al. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett. 2006; 16: 5517–22
   PubMed Web of Science ®Google Scholar
• Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Renock S, et al. A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors. Bioorg Med Chem Lett. 2006; 16: 5598–601
   PubMed Web of Science ®Google Scholar
• Warshakoon NC, Wu S, Boyer A, Kawamoto R, Renock S, Xu K, et al. Design and synthesis of a series of novel pyrazolopyridines as HIF 1-α prolyl hydroxylase inhibitors. Bioorg Med Chem Lett. 2006; 16: 5687–90
   PubMed Web of Science ®Google Scholar
• Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Bhatt RT, et al. Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors. Bioorg Med Chem Lett. 2006; 16: 5616–20
   Google Scholar
• Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007; 27: 2548–54
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung Y-L, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8: 143–53
   PubMed Web of Science ®Google Scholar
• Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem. 2005; 280: 41928–39
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005; 7: 77–85
   PubMed Web of Science ®Google Scholar
• Hewitson KS, Liénard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem. 2007; 282: 3293–301
   PubMed Web of Science ®Google Scholar
• Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005; 14: 2231–9
   PubMed Web of Science ®Google Scholar
• Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol. 1997; 29: 79–89
   PubMed Web of Science ®Google Scholar
• Grimm C, Hermann DM, Bogdanova A, Hotop S, Kilic Ü, Wenzel A, et al. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin Cell Dev Biol. 2005; 16: 531–8
   PubMed Web of Science ®Google Scholar
• Nangaku M, Eckardt K-U. Hypoxia and the HIF system in kidney disease. J Mol Med. 2007; 85: 1325–30
   Google Scholar
• Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke. 2003; 34: 1981–6
   PubMed Web of Science ®Google Scholar
• Ratan RR, Siddiq A, Aminova L, Lange PS, Langley B, Ayoub I, et al. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke. 2004; 35: 2687–9
   PubMedGoogle Scholar
• Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1α increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci. 2007; 27: 6320–32
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1α. Cardiovasc Res. 2008; 77: 463–70
   PubMed Web of Science ®Google Scholar
• Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler III AA, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol. 2005; 289: H542–8
   PubMed Web of Science ®Google Scholar
• Sridharan V, Guichard J, Bailey RM, Kasiganesan H, Beeson C, Wright GL. The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition. Am J Physiol Cell Physiol. 2007; 292: C719–28
   PubMed Web of Science ®Google Scholar
• Hill P, Shukla D, Tran MGB, Aragones J, Cook HT, Carmeliet P, et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008; 19: 39–46
   PubMed Web of Science ®Google Scholar
• Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem. 2005; 280: 41732–43
   PubMedGoogle Scholar
• Philipp S, Jürgensen JS, Fielitz J, Bernhardt WM, Weidemann A, Schiche A, et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail. 2006; 8: 347–54
   PubMedGoogle Scholar
• Bernhardt WM, Câmpean V, Kany S, Jürgensen J-S, Weidemann A, Warnecke C, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006; 17: 1970–8
   PubMed Web of Science ®Google Scholar
• Langsetmo I, Jacob C, Ho W-B, Stephenson R, Sirenko O, Sidhu P, et al. Inhibition of HIF prolyl hydroxylases with FG-4539 is neuroprotective in a mouse model of permanent focal ischemia. Stroke. 2006; 37: 731
   Google Scholar
• Wang Q, Guo R, Winmill R, Stephenson R, Pacleb J, Bin-Ho W, , et al. Renoprotective and therapeutic efficacy of the HIF prolyl hydroxylase inhibitor FG-4539 in experimental ischemia-reperfusion induced acute kidney injury. Am Soc Nephrol Renal Week 2006, Abstract TH-P01025.
   Google Scholar
• Macdougall IC, Eckardt K-U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006; 368: 947–53
   PubMed Web of Science ®Google Scholar
• Bunn HF. New agents that stimulate erythropoiesis. Blood. 2007; 109: 868–73
   PubMed Web of Science ®Google Scholar
• Klaus S, Langsetmo I, Flippin L, Arend M, Seeley T, Winmill R, , et al Induction of erythropoiesis in rodents by novel and distinct families of orally active HIF prolyl hydroxylase inhibitors. Keystone Symposia in Molecular, Cellular, Physiological, and Pathogenic Responses to Hypoxia; 15–20 Jan, 2008;, Vancouver, Canada. Abstract 301.
   Google Scholar
• Seeley TW, Sternlicht MD, Stephenson R, Arend M, Flippin L, Liu DY, , et al HIF prolyl hydroxylase inhibitors increase erythropoiesis without promotion of tumor progression in the presence or absence of concomitant chemotherapy. Keystone Symposia in Molecular, Cellular, Physiological, and Pathogenic Responses to Hypoxia; 15–20 Jan, 2008;, Vancouver, Canada. Abstract 364.
   Google Scholar
• Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007; 110: 2140–7
   PubMed Web of Science ®Google Scholar
• Wiecek A, Piecha G, Ignacy W, Schmidt R, Neumayer HH, Scigalla P, et al. Pharmacological stabilization of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease. Nephrol Dial Transplant 2005; 20(suppl 5)v195
   Google Scholar
• Frohna PA, Milwee S, Pinkett J, Lee T, Moore-Perry K, Chou J, , et al. Results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia. Am Soc Nephrol Renal Week 2007, Abstract SU-PO806.
   Google Scholar
• Bernhardt WM, Wiesener MS, Schmieder RE, Günzler V, Eckardt KU. The prolyl hydroxylase inhibitor FG-2216 stimulates EPO production in nephric and anephric dialysis patients—evidence for underutilized production capacity in liver and kidneys. Am Soc Nephrol Renal Week 2007, Abstract SA-PO784.
   Google Scholar
• Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9: 677–84
   PubMed Web of Science ®Google Scholar
• Vincent KA, Jiang C, Boltje I, Kelly RA. Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther. 2007; 14: 781–9
   PubMed Web of Science ®Google Scholar
• Pajusola K, Künnapuu J, Vuorikoski S, Soronen J, André H, Pereira T, et al. Stabilized HIF-1α is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J. 2005; 19: 1365–7
   PubMedGoogle Scholar
• Warnecke C, Griethe W, Weidemann A, Jürgensen JS, Willam C, Bachmann S, et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 2003; 17: 1186–8
   PubMed Web of Science ®Google Scholar
• Asikainen TM, Schneider BK, Waleh NS, Clyman RI, Ho WB, Flippin LA, et al. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung. Proc Natl Acad Sci USA. 2005; 102: 10212–7
   PubMed Web of Science ®Google Scholar
• Asikainen TM, Chang LY, Coalson JJ, Schneider BK, Waleh NS, et al. Improved lung growth and function through hypoxia-inducible factor in primate chronic lung disease of prematurity. FASEB J. 2006; 20: 1698–700
   PubMed Web of Science ®Google Scholar